During the corresponding time, Amarin Corp Plcuk saw a revenue deteriorated by -41.63 % year on year, sequentially revenue fell by -5.92 %. While revenue at the Amarin Corp Plcuk's corporate clients
Amarin Plcuk's Comment on Sales, Marketing and Customers
The company sells VASCEPA to customers who resell the product to retail pharmacies, which then distribute it to patients and healthcare providers. These customers possess significant bargaining power, resulting in higher discounts for the company. Payors affect market access through formulary placements and utilization management tools such as step edits and prior authorizations. Pharmacy Benefit Managers (PBMs) may impose disincentives, including higher deductibles, and have the option to exclude VASCEPA from coverage, as demonstrated by a large national PBM discontinuing coverage effective July 1, 2024. The market includes patients requiring treatment for conditions such as hypertriglyceridemia. The manufacture, packaging, and distribution of VASCEPA are regulated by the U.S. Food and Drug Administration and comparable foreign agencies, necessitating compliance with current Good Manufacturing Practices (cGMPs) and International Council for Harmonisation (ICH) guidelines. There are a limited number of manufacturers capable and willing to produce VASCEPA under these regulatory standards.
Revealing Mechanistic Insights into EPA Sheds Light on VASCEPA/VAZKEPA s Potential Mechanism of ActionAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 Data Further Advance Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action In recent years, there has been a growing interest in understanding the mechanisms behind the potential therapeutic benefits of eicosapentaenoic acid (EPA) a key component found in omega-3 fatty acids. This newfound focus has led to groundbreaking research that has paved the way for effective treatments utilizing EPA, such as VASCEPA/VAZKEPA. At the recent American College of Cardiology s 24th Annual Scientific Session (ACC....
Amarin Plcuk’s Comment on Sales, Marketing and Customers
The company sells VASCEPA to customers who resell the product to retail pharmacies, which then distribute it to patients and healthcare providers. These customers possess significant bargaining power, resulting in higher discounts for the company. Payors affect market access through formulary placements and utilization management tools such as step edits and prior authorizations. Pharmacy Benefit Managers (PBMs) may impose disincentives, including higher deductibles, and have the option to exclude VASCEPA from coverage, as demonstrated by a large national PBM discontinuing coverage effective July 1, 2024. The market includes patients requiring treatment for conditions such as hypertriglyceridemia. The manufacture, packaging, and distribution of VASCEPA are regulated by the U.S. Food and Drug Administration and comparable foreign agencies, necessitating compliance with current Good Manufacturing Practices (cGMPs) and International Council for Harmonisation (ICH) guidelines. There are a limited number of manufacturers capable and willing to produce VASCEPA under these regulatory standards.
Sources:
Amarin Corp Plcuk’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Amarin Corp Plcuk’s corporate clients.
For your research, we’ve provided 9 tables on Amarin Corp Plcuk corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
19.78 %